Green light for PolTREG to start producing next-generation T-reg cell therapies at its own pharmaceutical plant: the company just received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment.
We can now manufacture engineered T-reg cells at our state-of-the-art facility, including TCR-Tregs, CAR-Tregs and antigen-specific Tregs. These products offer exciting new ways to tackle the autoimmune diseases we are dedicated to help cure.
PolTREG is developing every possible Treg therapy for a wide range of auto-immune diseases. It has more than 17 years of experience treating type-1 diabetes and multiple sclerosis patients with polyclonal cells. Over that period, it has administered Treg cells to more than 100 people, in clinical trials and through a hospital exemption.
Our state-of-the-art manufacturing facility contains:
• ㅤ15 stand-alone production lines
• ㅤannual capacity of 1500 therapies
• ㅤ4000 sq. m of space
